A bibliometric and visualized analysis of liver fibrosis from 2002 to 2022
- PMID: 36459993
- DOI: 10.1111/jgh.16081
A bibliometric and visualized analysis of liver fibrosis from 2002 to 2022
Abstract
Fibrosis of the liver is a degenerative alteration that occurs in the majority of chronic liver disorders. Further progression can lead to cirrhosis, liver failure, and hepatocellular carcinoma, which can seriously affect the health and lives of patients. The field of liver fibrosis research has flourished in the last 20 years, with approximately 9000 articles retrieved from the Web of Science Core Collection database alone. In order to identify future research hotspots and potential paths in a thorough and scientifically reliable manner, it is important to organize and visualize the research on this topic from a holistic and very general perspective. This study used bibliometric analysis with CiteSpace and VOSviewer software to provide a quantitative analysis, hotspot mining, and commentary of articles published in the field of liver fibrosis over the last 20 years. This bibliometric analysis contains a total of 8994 articles with 45667 authors from 6872 institutions in 97 countries, published in 1371 journals and citing 156 309 references. The literature volume has steadily increased over the last 20 years. Research has focused on gastroenterology and hepatology, pharmacology and pharmacy, and medicine, research, and experimental areas. We found that the pathological mechanisms, diagnostic and quantitative methods, etiology, and antifibrotic strategies constitute the knowledge structure of liver fibrosis. Finding mechanisms for liver fibrosis regression, identifying precise noninvasive diagnostic and prognostic biomarkers, and creating efficient liver fibrosis patient treatments are the main goals of current research.
Keywords: CiteSpace; VOSviewer; bibliometrics; liver fibrosis.
© 2022 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Comment in
-
Editorial: Appraising liver fibrosis with eagle eyes.J Gastroenterol Hepatol. 2023 Mar;38(3):343. doi: 10.1111/jgh.16146. J Gastroenterol Hepatol. 2023. PMID: 36897268 No abstract available.
References
-
- Gines P, Krag A, Abraldes JG, Sola E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021; 398: 1359-1376.
-
- Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J. Hepatol. 2019; 70: 151-171.
-
- Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol. Aspects Med. 2019; 65: 37-55.
-
- Zhao M, Wang L, Wang M et al. Targeting fibrosis, mechanisms and cilinical trials. Signal Transduct. Target. Ther. 2022; 7: 206.
-
- Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014; 383: 1749-1761.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
